International Journal of Medicinal Chemistry

Copyright © 2012 Neha Pandit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. Vara Prasad, “New oxazolidinones,” Current Opinion in Microbiology, vol. 10, no. 5, pp. 454–460, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. B. Bozdogan and P. C. Appelbaum, “Oxazolidinones: activity, mode of action, and mechanism of resistance,” International Journal of Antimicrobial Agents, vol. 23, no. 2, pp. 113–119, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. K. E. Brighty, W. Kohlbrenner, and P. R. McGuirk, “Chapter 15. Recent developments in antibacterial resistance mechanisms,” Annual Reports in Medicinal Chemistry, vol. 28, pp. 141–150, 1993. View at Publisher · View at Google Scholar · View at Scopus
4. Y. Luo, L. Liu, L. Li, and Q. Deng, “Chiral resolution of racemic 4-phenyl(benzyl)-2-oxazolidone by use of molecularly imprinted polymers,” Chromatographia, vol. 65, no. 11-12, pp. 675–679, 2007. View at Publisher · View at Google Scholar · View at Scopus
5. S. J. Brickner, “Oxazolidinone antibacterial agents,” Current Pharmaceutical Design, vol. 2, no. 2, pp. 175–194, 1996. View at Google Scholar · View at Scopus
6. N. Alouane, A. Boutier, C. Baron, E. Vrancken, and P. Mangeney, “Remarkably efficient charcoal-promoted ring-closing carbonylations,” Synthesis, no. 5, pp. 860–864, 2006. View at Publisher · View at Google Scholar
7. A. Buzas and F. Gagosz, “Gold(I)-catalyzed formation of 5-methylene-1,3-oxazolidin-2-ones,” Synlett, no. 17, pp. 2727–2730, 2006. View at Publisher · View at Google Scholar
8. R. Robles-Machín, J. Adrio, and J. C. Carretero, “Gold-catalyzed synthesis of alkylidene 2-oxazolidinones and 1,3-oxazin-2-ones,” Journal of Organic Chemistry, vol. 71, no. 13, pp. 5023–5026, 2006. View at Publisher · View at Google Scholar · View at PubMed
9. T. Munegumi, I. Azumaya, T. Kato, H. Masu, and S. Saito, “[3+2] Cross-coupling reactions of aziridines with isocyanates catalyzed by nickel(II) iodide,” Organic Letters, vol. 8, no. 3, pp. 379–382, 2006. View at Publisher · View at Google Scholar · View at PubMed
10. Y. Osa, Y. Hikima, Y. Sato et al., “Convenient synthesis of oxazolidinones by the use of halomethyloxirane, primary amine, and carbonate salt,” Journal of Organic Chemistry, vol. 70, no. 14, pp. 5737–5740, 2005. View at Publisher · View at Google Scholar · View at PubMed
11. A. Bøgevig, K. Juhl, N. Kumaragurubaran, W. Zhuang, and K. A. Jørgensen, “Direct catalytic asymmetric amination of aldehydes: synthesis of evans oxazolidinones and a-AminoAcid,” Angewandte Chemie International Edition, vol. 41, p. 1790, 2002. View at Google Scholar
12. H. P. Buchstaller, “Solid-phase synthesis of oxazolidinones by cycloaddition of resin-bound epoxides with isocyanates,” Journal of Combinatorial Chemistry, vol. 5, no. 6, pp. 789–793, 2003. View at Publisher · View at Google Scholar · View at PubMed
13. K.-J. Hwang, C.-M. Yu, N.-K. Choi, and K.-H. Park, “A convenient diastereoselective synthesis of oxazolidinone: approach to unusal amino acid statine,” Bulletin of the Korean Chemical Society, vol. 15, pp. 527–532, 1994. View at Google Scholar
14. G. Bratulescu, “An excellent procedure for the synthesis of oxazolidin-2-ones,” Synthesis, no. 20, pp. 3111–3112, 2007. View at Publisher · View at Google Scholar
15. D. M. Gleave, S. J. Brickner, P. R. Manninen et al., “Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 10, pp. 1231–1236, 1998. View at Publisher · View at Google Scholar · View at Scopus
16. D. L. Stevens, B. Dotter, and K. Madaras-Kelly, “A review of linezolid: the first oxazolidinone antibiotic,” Expert Review of Anti-Infective Therapy, vol. 2, no. 1, pp. 51–59, 2004. View at Google Scholar · View at Scopus
17. F. Ntziora and M. E. Falagas, “Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 6, pp. 606–611, 2007. View at Google Scholar · View at Scopus
18. D. Andes, M. L. Van Ogtrop, J. Peng, and W. A. Craig, “In vivo pharmacodynamics of a new oxazolidinone (linezolid),” Antimicrobial Agents and Chemotherapy, vol. 46, no. 11, pp. 3484–3489, 2002. View at Publisher · View at Google Scholar · View at Scopus
19. CIMS, CMP Medica India Private Limited, 2010.
20. Zurenko et al., “In vitro antibacterial activity of U-100592 and U-100766, novel oxazolidinones antibiotics,” in Proceedings of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '95), pp. 150–11, 1995.
21. C. W. Ford et al., in Proceedings of the 35th Internscience Conference on Antimicrobial Agents and Chemotherapy, 1995.
22. D. J. Abraham, Ed., BURGER’S Medicinal chemistry and drug discovery, vol. 5, Willey Interscience, 6th edition, 1997.
23. D. J. Abraham, Ed., BURGER’S Medicinal Chemistry and Drug Discovery, vol. 2, Willey Interscience, 1996.
24. D. J. Diekema and R. N. Jones, “Oxazolidinones: a review,” Drugs, vol. 59, no. 1, pp. 7–16, 2000. View at Google Scholar · View at Scopus
25. V. A. Pankratov, T. M. Frenkel', and A. M. Fainleib, “2-oxazolidinone,” Russian Chemical Review, vol. 52, no. 6, p. 576, 1983. View at Google Scholar
26. B. K. Srivastava, R. Soni, J. Z. Patel, M. R. Jain, and P. R. Patel, “Oxazolidinone antibacterials and our experience,” Anti-Infective Agents in Medicinal Chemistry, vol. 7, no. 4, pp. 258–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
27. M. R. Barbachyn and C. W. Ford, “Oxazolidinone structure-activity relationships leading to linezolid,” Angewandte Chemie, vol. 42, no. 18, pp. 2010–2023, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. N. Gandhi, B. K. Srivastava, V. B. Lohray, and B. B Lohray, “Novel anti-infective compounds,” Tetrahedron Letters, vol. 45, pp. 6269–6272, 2004. View at Google Scholar
29. P. Senci, M. Caspani, F. Ripamonti, and R. Ciabatti, “Oxazolidinone antibacterials and our experience,” Journal of the Chemical Society, Perkin Transactions, vol. 1, p. 2345, 1994. View at Google Scholar
30. C. A. Quesnelle, P. Gill, S. Roy et al., “Biaryl isoxazolinone antibacterial agents,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 11, pp. 2728–2733, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. G. Wang, J. R. Ella-Menye, and V. Sharma, “Synthesis and antibacterial activities of chiral 1,3-oxazinan-2-one derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 8, pp. 2177–2181, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. R. Griera, C. Cantos-Llopart, M. Amat, J. Bosch, J.–C. del Castillo, and J.B Huguet, “New potential antibacterials: a synthetic route to N-aryloxazolidinone/3-aryl tetrahydroisoquinoline hybrids,” Bioorganic & Medicinal Chemistry Letters, vol. 15, p. 2515, 2005. View at Google Scholar
33. M. L. Hammond and Y. Fukuda, “Oxazolidinones antibiotics and derivatives,” Pct International Application WO2005/005399, Merck & Co.-Kyorin Pharmaceutical, 2005. View at Google Scholar
34. N. Selvakumar, B. Yadi Reddy, G. Sunil Kumar et al., “Synthesis of novel tricyclic oxazolidinones by a tandem SN₂ and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 16, pp. 4416–4419, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. A. L. Choy, J. V. N. Vara Prasad, F. E. Boyer, M. D. Huband, and M. R. Dermyer, “Synthesis and SAR of novel conformationally restricted oxazolidinones possessing Gram-positive and fastidious Gram-negative antibacterial activity. Part 2: Amino substitutions on heterocyclic D-ring system,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 16, pp. 4699–4702, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. B. B. Lohray, V. B. Lohray, B. K. Srivastava et al., “Oxazolidinone: search for highly potent antibacterial,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 12, pp. 3139–3142, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannich ketones of oxazolidinones as antibacterial agents,” European Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 989–992, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. B. Das, S. Rudra, A. Yadav et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700,” Bioorganic and Medicinal Chemistry Letters, vol. 15, p. 4261, 2005. View at Google Scholar
39. S. K. Agrawal, S. S. Pandey, M. M. Samuel, G. Singh, and S. Chithra, “New antibacterial agents,” Pct International Application number WO2005/090339, Orchid Chemicals and Pharmaceuticals, 2005. View at Google Scholar
40. A. R. Renslo, G. W. Luehr, S. Lam et al., “Synthesis and structure-activity studies of antibacterial oxazolidinones containing dihydrothiopyran or dihydrothiazine C-rings,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 13, pp. 3475–3478, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. X. Zhai, G. G. Zhang, D. H. Gou, J. P. Liu, and P. Gong, “Modification of novel oxazolidinone derivatives at C-5 side chain and their antibacterial activities,” Acta Pharmaceutica Sinica, vol. 41, no. 10, pp. 985–989, 2006. View at Google Scholar · View at Scopus
42. R. Schaadt, D. Sweeney, D. Shinabarger, and G. Zurenko, “The in vitro activity of TR-701, a novel oxazolidinone antibacterial agent,” in Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '07), Chicago, Ill, USA, September 2007.
43. B. Das, S. Rudra, S. Sangita, M. Salman, and A. Rattan, “Oxazolidinone derivatives as antimicrobials,” Pct International Application number WO2006/109156, Ranbaxy Laboratories, 2006. View at Google Scholar
44. O. A. Phillips, E. E. Udo, A. A. M. Ali, and S. M. Samuel, “Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 42, no. 2, pp. 214–225, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. H. Fan, Y. Chen, Z. Jiang et al., “Synthesis and biological evaluation of new N-linked 5-triazolylmethyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1706–1714, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. N. Selvakumar, G. S. Kumar, A. Malar Azhagan et al., “Synthesis, SAR and antibacterial studies on novel chalcone oxazolidinone hybrids,” European Journal of Medicinal Chemistry, vol. 42, no. 4, pp. 538–543, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. F. Reck, F. Zhou, C. J. Eyermann et al., “Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility,” Journal of Medicinal Chemistry, vol. 50, no. 20, pp. 4868–4881, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. J. Liu, B. He, A. Yu, and W. Zhou, “Synthesis and antibacterial activity of substituted oxotriazolylphenyl oxazolidinones,” Chemical Biology and Drug Design, vol. 70, no. 1, pp. 65–69, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. T. J. Poel, R. C. Thomas, W. J. Adams et al., “Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl] -2-oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound,” Journal of Medicinal Chemistry, vol. 50, no. 24, pp. 5886–5889, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. S. Rudra, A. Yadav, A. V. S. Raja Rao et al., “Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 24, pp. 6714–6719, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. F. Reck, F. Zhou, G. Zainoun, D. Carcanague, C. Eyermann, and M. Gravestock, “Novel acyclic substituted (pyridin-3-yl) phenyl oxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and improved solubility,” in Proceedings of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March-April 2007.
52. M. Cano, A. Palomer, and A. Guglietta, “Oxazolidinone derivatives and use thereof as antibiotics,” Pct International Application number WO2007/000432, Ferrer International S.A., 2007. View at Google Scholar
53. B. K. Srivastava, R. Soni, J. Z. Patel, M. R. Jain, and P. R. Patel, “Oxazolidinone antibacterials and our experience,” Anti-Infective Agents in Medicinal Chemistry, vol. 7, no. 4, pp. 258–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
54. J. F. Barrett, “Linezolid pharmacia corp,” Current Opinion in Investigational Drugs, vol. 1, no. 2, pp. 181–187, 2000. View at Google Scholar · View at Scopus
55. Y. Cui, Y. Dang, Y. Yang, S. Zhang, and R. Ji, “Antibacterial activity of YC-20, a new oxazolidinone,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 2, pp. 452–454, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. S. Lemaire, K. Kosowska-Shick, P. C. Appelbaum, P. M. Tulkens, and F. Van Bambeke, “Radezolid (RX RX-1741), a novel oxazolidinone oxazolidinone, accumulates, extensively within human macrophages and PMNs and shows activity towards intracellular linezolid linezolid-sensitive and linezolid linezolid-resistant Staphylococcus aureus,” in Proceedings of the 26th International Congress of Chemotherapy and Infection, Torranto, Canada, June 2009.
57. http://www.rib-x.com/pipeline/rx_1741.
58. S. D. Brown and M. M. Traczewski, “Comparative in Vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 2063–2069, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. A. Wookey, P. J. Turner, J. M. Greenhalgh, M. Eastwood, J. Clarke, and C. Sefton, “AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro,” Clinical Microbiology and Infection, vol. 10, no. 3, pp. 247–254, 2004. View at Publisher · View at Google Scholar · View at Scopus
60. A. P. Johnson, M. Warner, and D. M. Livermore, “In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci,” Journal of Antimicrobial Chemotherapy, vol. 50, no. 1, pp. 89–93, 2002. View at Google Scholar · View at Scopus
61. B. K. Srivastava, P. B. Kapadnis, P. Pandya, and V. B. Lohray, “Novel Mannich ketones of oxazolidinones as antibacterial agents,” European Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 989–992, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
62. J. A. Demaray, J. E. Thuener, M. N. Dawson, and S. J. Sucheck, “Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 17, pp. 4868–4871, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. N. Adibpour, A. Khalaj, and S. Rajabalian, “Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,” European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 19–24, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. O. A. Phillips, E. E. Udo, M. E. Abdel-Hamid, and R. Varghese, “Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones,” European Journal of Medicinal Chemistry, vol. 44, no. 8, pp. 3217–3227, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
65. O. A. Phillips, E. E. Udo, A. A. M. Ali, and N. Al-Hassawi, “Synthesis and antibacterial activity of 5-substituted oxazolidinones,” Bioorganic and Medicinal Chemistry, vol. 11, no. 1, pp. 35–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
66. H. Fan, G. Xu, Y. Chen et al., “Synthesis and antibacterial activity of oxazolidinones containing triazolyl group,” European Journal of Medicinal Chemistry, vol. 42, no. 8, pp. 1137–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. Oral anticoagulant rivaroxaban (Xarelto) cuts deep vein thrombosis risk by 82%: Bayer, http://www.dancewithshadows.com/pillscribe/oral-anticoagulant-rivaroxaban-xarelto-cuts-deep-vein-thrombosis-risk-by-82-bayer/.
68. S. Roehrig, A. Straub, J. Pohlmann et al., “Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4- (3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor,” Journal of Medicinal Chemistry, vol. 48, no. 19, pp. 5900–5908, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. M. R. Barbachyn, D. K. Hutchinson, S. J. Brickner et al., “Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 680–685, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
70. M. H. Cynamon, S. P. Klemens, C. A. Sharpe, and S. Chase, “Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1189–1191, 1999. View at Google Scholar · View at Scopus
71. R. R. Ramsay and M. B. Gravestock, “Monoamine oxidases: to inhibit or not to inhibit,” Mini Reviews in Medicinal Chemistry, vol. 3, no. 2, pp. 129–136, 2003. View at Google Scholar · View at Scopus
72. A. Malnoe and M. Strolin Benedetti, “Metabolic fate of 3-(3-methylphenyl)-5-hydroxymethyl-2-oxazolidone (toloxatone), a new antidepressant agent, in man,” Xenobiotica, vol. 9, no. 5, pp. 281–288, 1979. View at Google Scholar · View at Scopus
73. W. Kostowski, A. Plaznik, A. Bidzinski, E. Rosnowska, M. Jessa, and M. Nazar, “Studies on antidepressant action of a new oxazolidinone derivative AS-8,” Polish Journal of Pharmacology, vol. 46, no. 1-2, pp. 15–20, 1994. View at Google Scholar · View at Scopus
74. S. Katsumura, S. Iwama, T. Matsuda, T. Tani, S. Fujii, and K. Ikeda, “Synthesis of oxazolidinone phospholipid analogue as a new inhibitor of phospholipase A₂,” Bioorganic and Medicinal Chemistry Letters, vol. 3, no. 12, pp. 2703–2706, 1993. View at Publisher · View at Google Scholar
75. J. A. Sternberg, D. Geffken, and J. B. Adams Jr., “Oxazolidinones: a new class of agricultural fungicides,” in Synthesis and Chemistry of Agrochemicals, vol. 686 of ACS Symposium Series, chapter 22, pp. 216–227, 1998. View at Google Scholar
76. J. A. Sternberg, D. Geffken, J. B. Adams et al., “Famoxadone: the discovery and optimisation of a new agricultural fungicide,” Pest Management Science, vol. 57, no. 2, pp. 143–152, 2001. View at Google Scholar · View at Scopus
77. D. B. Jordan, R. S. Livingston, and J. J. Bisaha, “Oxazolidinones: a new chemical class of fungicides and inhibitors of mitochondrial cytochrome bc₁ function,” Pesticide Science, vol. 55, no. 2, pp. 213–215, 1999. View at Google Scholar
78. W. J. Welstead, G. C. Helsley, C. R. Taylor et al., “5-(2-Aminoethyl)-2-oxazolidinones with central nervous system depressant and antiinflammatory activity,” Journal of Medicinal Chemistry, vol. 16, no. 10, pp. 1129–1132, 1973. View at Google Scholar · View at Scopus
79. “Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders,” United States Patent, 5643907.
80. M. Masaki and H. Shinozaki, “A new class of potent centrally acting muscle relaxants: pharmacology of oxazolidinones in rat decerebrate rigidity,” British Journal of Pharmacology, vol. 89, no. 1, pp. 219–228, 1986. View at Google Scholar · View at Scopus
81. H. J. Lewerenz, D. W. Bleyl, and W. Schnaak, “Effects of 5-vinyloxazolidine-2-thione on lactating rats and their sucklings,” Die Nahrung, vol. 36, no. 4, pp. 388–393, 1992. View at Google Scholar · View at Scopus
82. N. Zenker, L. S. Hubbard, and J. Wright, “Inhibition of dopamine β-hydroxylase by goitrin, a natural antithyroid compound,” Journal of Natural Products, vol. 51, no. 5, pp. 862–865, 1988. View at Google Scholar · View at Scopus
83. M. McMillan, E. A. Spinks, and G. R. Fenwick, “Preliminary observations on the effect of dietary Brussels sprouts on thyroid function,” Human Toxicology, vol. 5, no. 1, pp. 15–19, 1986. View at Google Scholar · View at Scopus
84. M. Artico, G. De Martino, and R. Giuliano, “Research on compounds with antiblastic activity. XL. Synthesis of 3-p-(2',5'-dimethoxy-4'-(N,N-bis-( -chloroethyl)-amino)benzylideneamino)phenyl-2-oxazolidinone (GEA 29 ; BAY a 5850) and its analogues,” Il Farmaco; Edizione Scientifica, vol. 26, no. 9, pp. 771–783, 1971. View at Google Scholar · View at Scopus
85. H. Onda, F. M. E. Wagenlehner, N. Lehn, and K. G. Naber, “In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections,” International Journal of Antimicrobial Agents, vol. 18, no. 3, pp. 263–266, 2001. View at Publisher · View at Google Scholar · View at Scopus
86. http://www.chemicalbook.com/ChemicalProductProperty_EN_CB71179461.htm.
87. D. G. Musson, S. M. Maglietto, and S. S. Hwang, “Simultaneous quantification of cycloserine and its prodrug acetylacetonylcycloserine in plasma and urine by high-performance liquid chromatography using ultraviolet absorbance and fluorescence after post-column derivatization,” Journal of Chromatography, vol. 414, no. 1, pp. 121–129, 1987. View at Google Scholar
88. T. Mathur, M. Kumar, T. K. Barman et al., “Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, pp. 1087–1095, 2011. View at Publisher · View at Google Scholar · View at PubMed
89. E. Skripkin, T. S. McConnell, J. DeVito et al., “Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 10, pp. 3550–3557, 2008. View at Publisher · View at Google Scholar · View at PubMed
90. J. J. Hilliard, J. Fernandez, J. Melton et al., “In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 5, pp. 2028–2033, 2009. View at Publisher · View at Google Scholar · View at PubMed
91. J. B. Locke, M. Hilgers, and K. J. Shaw, “Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700),” Antimicrobial Agents and Chemotherapy, vol. 53, no. 12, pp. 5265–5274, 2009. View at Publisher · View at Google Scholar · View at PubMed
92. J. B. Locke, G. Morales, M. Hilgers et al., “Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5352–5355, 2010. View at Publisher · View at Google Scholar · View at PubMed
93. E. Y. Cheung, M. L. Peterson, R. Chiarella, and B. M. Foxman, “A novel oxazolidinone anti-biotic: RWJ-416457,” Acta Crystallographica Section C, vol. 66, no. 5, pp. o249–o251, 2010. View at Publisher · View at Google Scholar · View at PubMed
94. J. B. Locke, J. Finn, M. Hilgers et al., “Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 5337–5343, 2010. View at Publisher · View at Google Scholar · View at PubMed
95. New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia, http://www.prnewswire.com/news-releases/new-phase-4-study-shows-higher-rates-of-clinical-and-microbiological-success-for-zyvox-versus-vancomycin-in-mrsa-nosocomial-pneumonia-105422943.html.